San Diego, CA, United States of America

Han Zhang

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 8.5

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2020-2024

Loading Chart...
Loading Chart...
5 patents (USPTO):

Title: **Innovative Contributions of Han Zhang in Cancer Treatment**

Introduction

Han Zhang is an inventive mind based in San Diego, CA, whose contributions to pharmaceuticals, particularly in the fight against cancer, have garnered him five patents. His research focuses on novel macrocyclic compounds that hold promise in inhibiting specific cancer-related targets.

Latest Patents

Zhang's recent patents include significant advancements in macrocyclic compounds. These compounds are designed to inhibit SRC, MET, and CSF1R, which are critical in cancer progression. The patents detail not only the compounds themselves but also pharmaceutical compositions containing these innovations and methods of using them to treat various forms of cancer.

Career Highlights

Currently, Han Zhang is affiliated with Turning Point Therapeutics, Inc., where he utilizes his expertise to drive forward initiatives that enhance cancer treatment options. His academic and professional journey has led him to focus on formulating effective therapeutic agents, making a notable impact in oncological research.

Collaborations

Zhang works alongside esteemed colleagues such as Evan W Rogers and Jingrong Jean Cui, contributing to a collaborative environment that fosters innovation and scientific breakthroughs. The synergy within his team is pivotal to the success of their research endeavors.

Conclusion

In summary, Han Zhang stands out as a significant contributor to cancer research through his innovative work on macrocyclic compounds. His patents not only reflect his commitment to advancing medical science but also highlight the potential impact of these innovations on cancer treatment modalities.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…